All News

Patients who were more satisfied with the communication they received from cancer care providers often had better health outcomes at lower costs.

Researchers have developed a novel peptide drug that has the potential to reduce tumor growth and slow down the spread of cancer cells.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Treating patients’ stress and poor sleep may help reduce the risk of depression in multiple sclerosis.

A phase 1 trial evaluating the safety and tolerability of PRN2246, a Bruton's tyrosine kinase (BTK) inhibitor, found the drug having no serious medication-related adverse events in healthy volunteers while also being able to reach the brain.

Pharmacy Times® has launched a video tour of our updated website. Viewers are introduced to a variety of unique features, and will learn to access each of them.

The 2018-19 Best Hospital’s Honor Roll is a distinction awarded to 20 hospitals delivering exceptional treatment across multiple areas of care.

The Mayo Clinic in Rochester, Minnesota, is at the top of the Best Hospitals ranking by U.S. News & World Report, and is included in the Top 5 lists for 3 selected specialties.

Globally, lung cancer mortality rates among women are projected to increase by 43% from 2015 to 2030.

Botox injections found to decrease urinary incontinence and improve quality of life for patients with multiple sclerosis.

Organ transplant recipients who received infected kidneys were cured of hepatitis C after taking antiviral therapy following the procedure.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Vizuri Health Sciences’ PainBloc24®, a new topical analgesic product containing capsaicin, has arrived on the retail market.

The designation was based on data from 7 clinical trials over the past decade, which assessed omalizumab’s efficacy and safety versus various food allergens, such as peanut, milk, and egg.

Officials with the FDA have approved migalastat (Galafold, Amicus Therapeutics), the first oral medication for the treatment of adults with Fabry disease.

Migalastat (Galafold, Amicus Therapeutics) is the first oral medication for the treatment of adults with Fabry disease, a rare genetic disorder.

Canine animal assistance improves attentiveness and social skills in children with ADHD, according to recent study.

The FDA permitted marketing of the first mobile medical app that can be used as a method of contraception to prevent pregnancy.

Midazolam Nasal Spray—from global biopharmaceutical company UCB, Brussels, Belgium (UCB)—has been previously granted Orphan Drug and Fast Track designations by the FDA

The annual cost of treating cancer is projected to rise to $173 billion by 2020, a 39% increase since 2010.

The guidelines fill an unmet clinical need for a standard care consensus on gestational trophoblastic neoplasia, a group of rare cancers that affect pregnant women.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Pharmacy benefit manager says it retained approximately $300 million in drug rebates, well under the $2 billion amount that some projected.

The FDA has approved a combined hormonal contraceptive for women that is the first vaginal ring contraceptive that can be used for an entire year.

Officials with the FDA have approved the first targeted treatment for adult patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, a rare and often fatal disease.

Patisiran (Onpattro, Alnylam Pharmaceuticals) is indicated for the treatment of adult patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR), a rare genetic disease.

The FDA has permitted marketing of Natural Cycles, the first mobile medical app that can be used as a method of contraception to prevent pregnancy.